Trump Admin Cracks Down on Big Pharma's Misleading Drug Ads
The Trump administration is targeting misleading drug advertisements by proposing new rules to close a 1997 loophole allowing pharmaceutical companies to conceal safety risks in ads. The move aims to increase transparency and accuracy in pharmaceutical marketing.
The Trump administration is cracking down on deceptive drug advertising by proposing new rules to close a 1997 loophole that allows pharmaceutical companies to hide safety risks from consumers through broadcast and digital ads, aiming to increase transparency in the industry. The rule making process seeks to curb misleading marketing practices that can influence doctors' prescribing decisions and ultimately impact patient health. By strengthening regulations on advertising, the administration hopes to promote more responsible and truthful interactions between pharma companies and healthcare professionals.
